Role of serological rapid antibody test in the management of possible COVID-19 cases

Table 1 Demographic and clinical characteristics of serologically positive reverse transcription polymerase chain reaction negative coronavirus disease 2019 patients

	n (%)
Agein yr
mean ± SD	63.2 ± 13.1
Gender
Male/Female	11/11
Symptoms, n (%)
Cough	20 (90.9)
Dyspnea	14 (63.6)
Fever	10 (45.4)
Chest pain	8 (36.3)
Duration in d, mean ± SD
From first symptom to admission	8.6 ± 7.2
Hospital stay	11.2 ± 5.4
From symptoms to antibody test	24 ± 17
Drug treatment	7.9 ± 3.2

Table 2 Radiological findings and drug regiments of serologically positive reverse transcription polymerase chain reaction negative coronavirus disease 2019 patients

	n (%)
Radiology
GGO	17 (77.2)
Consolidation	11 (50)
Nodular infiltrates	4 (18.1)
Fibroreticular infiltrates	3 (5.9)
Drug regimens
HCQ+Azithromycine + Favipravir	11 (50)
HCQ+Azithromycine	7 (31.8)
Favipravir	4 (18.1)

GGO: Ground-Glass Opacities; HCQ: Hydroxychloroquine.

Table 3 The laboratory parameters of serologically positive reverse transcription polymerase chain reaction negative coronavirus disease 2019 patients

Value	mean ± SD
ESR in mm/h	68.5 ± 41.7
LDH in U/L	362 ± 152
CRP in mg/L	95 ± 101
Ferritinin μg/L	778 ± 684
WBCs	8621 ± 3549
Lymphocytes, n (%)	1430 ± 530
Lymphocytes, n (%)	22 ± 10.8
Neutrophils, n (%)	5390 ± 2450
Neutrophils as %	70.5 ± 12.3
D-Dimer in mg/L	1875 ± 2757
Procalcitonin in mg/L	0.15 ± 0.03

CRP: C-reactive protein; ESR: Erythrocyte sedimentation rate; LDH: Lactate dehydrogenase; WBCs:White blood cells.